Cargando…

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma

Glioblastoma WHO IV (GBM), the most common primary brain tumor in adults, is a heterogenous malignancy that displays a reprogrammed metabolism with various fuel sources at its disposal. Tumor cells primarily appear to consume glucose to entertain their anabolic and catabolic metabolism. While less e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Trang T. T., Shang, Enyuan, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Siegelin, Markus D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563867/ https://www.ncbi.nlm.nih.gov/pubmed/36230918 http://dx.doi.org/10.3390/cells11192956

Ejemplares similares

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020)

Targeting cellular respiration as a therapeutic strategy in glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2023)

Targeting super-enhancers reprograms glioblastoma central carbon metabolism
por: Nguyen, Trang T.T., et al.
Publicado: (2021)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems
por: Nguyen, Trang T. T., et al.
Publicado: (2020)

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS
por: Nguyen, Trang, et al.
Publicado: (2021)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
por: Nguyen, Trang T.T., et al.
Publicado: (2022)

Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2021)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors
por: Nguyen, Trang Thi Thu, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

A triple drug combination as a novel anti-glioma therapy?
por: Zhang, Yiru, et al.
Publicado: (2018)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
por: Dwucet, Annika, et al.
Publicado: (2021)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

The limitations of targeting MEK signalling in Glioblastoma therapy
por: Selvasaravanan, Karthika D., et al.
Publicado: (2020)

ETMM-05. LACTIC ACID FACILITATES GLIOBLASTOMA GROWTH THROUGH MODULATION OF THE EPIGENOME
por: Torrini, Consuelo, et al.
Publicado: (2021)

Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition
por: Nguyen, Trang Thi Thu, et al.
Publicado: (2019)

The effects of PI3K-mediated signalling on glioblastoma cell behaviour
por: Langhans, Julia, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death
por: Karpel-Massler, Georg, et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Comment in Response to “Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina”
por: Westhoff, Mike-Andrew, et al.
Publicado: (2020)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells
por: Hasslacher, Sebastian, et al.
Publicado: (2018)

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
por: Ströbele, Stephanie, et al.
Publicado: (2015)

Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach
por: Mettang, Melanie, et al.
Publicado: (2018)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

Killing Me Softly—Future Challenges in Apoptosis Research
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Cell death-based treatment of childhood cancer
por: Westhoff, Mike-Andrew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uqs36ddtjtf5t2mh9280knf5c9